Literature DB >> 21502224

Familial aggregation of autoimmune disease in juvenile dermatomyositis.

Timothy B Niewold1, Stephanie C Wu, Molly Smith, Gabrielle A Morgan, Lauren M Pachman.   

Abstract

OBJECTIVE: Familial aggregation of autoimmune diseases likely reflects shared pathogenic factors between different diseases. Familial aggregation of autoimmunity has not been examined in juvenile dermatomyositis. Interferon-α is thought to be a pathogenic factor in both systemic lupus erythematosus and juvenile dermatomyositis, and we have previously demonstrated familial aggregation of serum interferon-α.
METHODS: Family histories were obtained from 304 families of children with juvenile dermatomyositis via 3-generation structured interviews performed by the same person. Rates of autoimmune disease in families of children with juvenile dermatomyositis were compared with published population rates. Serum interferon-α, tumor necrosis factor-α, and neopterin were measured using standard techniques.
RESULTS: A total of 51% of families of children with juvenile dermatomyositis reported at least 1 additional member affected by an autoimmune disease. In particular, both type 1 diabetes and systemic lupus erythematosus were significantly more common than would be expected (odds ratio >5, P ≤ 1 × 10(-7) for both). Pedigree analysis showed particularly strong familial clustering of systemic lupus erythematosus with little decrease in incidence across generations, suggesting the possibility of rare causal genes with large effect. Untreated subjects with juvenile dermatomyositis with a family history of systemic lupus erythematosus had higher serum interferon-α than those who did not (P = .047).
CONCLUSIONS: We find strong familial aggregation of specific autoimmune diseases in families of children with juvenile dermatomyositis, suggesting that these conditions share pathogenic factors. Higher serum interferon-α in juvenile dermatomyositis patients with a family history of systemic lupus erythematosus suggesting that interferon-α is one such shared factor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502224      PMCID: PMC3081190          DOI: 10.1542/peds.2010-3022

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  50 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Epidemiology of systemic lupus erythematosus.

Authors:  Michelle Petri
Journal:  Best Pract Res Clin Rheumatol       Date:  2002-12       Impact factor: 4.098

3.  Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis.

Authors:  Nikki N Kim; Peter A Lio; Gabrielle A Morgan; James N Jarvis; Lauren M Pachman
Journal:  Arch Dermatol       Date:  2011-03-21

4.  Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases.

Authors:  L R Ginn; J P Lin; P H Plotz; S J Bale; R L Wilder; A Mbauya; F W Miller
Journal:  Arthritis Rheum       Date:  1998-03

5.  US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry.

Authors:  Eduardo P Mendez; Rebecca Lipton; Rosalind Ramsey-Goldman; Phil Roettcher; Susan Bowyer; Alan Dyer; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2003-06-15

6.  TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications.

Authors:  L M Pachman; M R Liotta-Davis; D K Hong; T R Kinsella; E P Mendez; J M Kinder; E H Chen
Journal:  Arthritis Rheum       Date:  2000-10

7.  Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.

Authors:  Robert S Stern; Tamar Nijsten; Steven R Feldman; David J Margolis; Tara Rolstad
Journal:  J Investig Dermatol Symp Proc       Date:  2004-03

8.  Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study.

Authors:  Alessio Fasano; Irene Berti; Tania Gerarduzzi; Tarcisio Not; Richard B Colletti; Sandro Drago; Yoram Elitsur; Peter H R Green; Stefano Guandalini; Ivor D Hill; Michelle Pietzak; Alessandro Ventura; Mary Thorpe; Debbie Kryszak; Fabiola Fornaroli; Steven S Wasserman; Joseph A Murray; Karoly Horvath
Journal:  Arch Intern Med       Date:  2003-02-10

9.  Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501.

Authors:  A M Reed; L Pachman; C Ober
Journal:  Hum Immunol       Date:  1991-12       Impact factor: 2.850

10.  Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.

Authors:  Maureen D Mayes; James V Lacey; Jennifer Beebe-Dimmer; Brenda W Gillespie; Brenda Cooper; Timothy J Laing; David Schottenfeld
Journal:  Arthritis Rheum       Date:  2003-08
View more
  35 in total

Review 1.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Authors:  Lauren M Pachman; Amer M Khojah
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

Review 2.  Interferon alpha as a primary pathogenic factor in human lupus.

Authors:  Timothy B Niewold
Journal:  J Interferon Cytokine Res       Date:  2011-09-16       Impact factor: 2.607

Review 3.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

4.  Interferon-α induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis.

Authors:  Imelda Balboni; Timothy B Niewold; Gabrielle Morgan; Cindy Limb; Maija-Leena Eloranta; Lars Rönnblom; Paul J Utz; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2013-09

Review 5.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 6.  Advances in lupus genetics.

Authors:  Timothy B Niewold
Journal:  Curr Opin Rheumatol       Date:  2015-09       Impact factor: 5.006

Review 7.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 8.  Monogenic systemic lupus erythematosus: insights in pathophysiology.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-05-15       Impact factor: 2.631

Review 9.  Immunological biomarkers in dermatomyositis.

Authors:  Jeannette M Olazagasti; Timothy B Niewold; Ann M Reed
Journal:  Curr Rheumatol Rep       Date:  2015-11       Impact factor: 4.592

Review 10.  The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.

Authors:  Consuelo M López de Padilla; Timothy B Niewold
Journal:  Gene       Date:  2015-09-26       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.